Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)

Date

09 Oct 2016

Session

NSCLC, metastatic 1

Presenters

Luis Paz-Ares

Citation

Annals of Oncology (2016) 27 (6): 1-36. 10.1093/annonc/mdw435

Authors

L. Paz-Ares1, E.H. Tan2, L. Zhang3, V. Hirsh4, K. O'Byrne5, M. Boyer6, J.C. Yang7, T.S.K. Mok8, K.H. Lee9, S. Lu10, Y. Shi11, S. Kim12, J. Laskin13, D. Kim14, S. Laurie15, K. Kölbeck16, J. Fan17, N. Dodd18, A. Märten19, K. Park20

Author affiliations

  • 1 Medical Oncology, Hospital Universitario Doce de Octubre and CNIO, 28041 - Madrid/ES
  • 2 Division Of Medical Oncology, National Cancer Centre, Singapore/SG
  • 3 State Key Laboratory Of Oncology In South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou/CN
  • 4 Department Of Oncology, McGill University, Montreal/CA
  • 5 Medical Oncology, Princess Alexandra Hospital and Queensland University of Technology, Brisbane/AU
  • 6 Department Of Medical Oncology, Chris O'Brien Lifehouse, Camperdown/AU
  • 7 Department Of Oncology, National Taiwan University Hospital and National Taiwan University, Taipei/TW
  • 8 Key Laboratory Of South China, Department Of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong/HK
  • 9 Yeungnam University Medical Center, Chungbuk National University Hospital, Cheongju, Chungbuk/KR
  • 10 Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai/CN
  • 11 Department Of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing/CN
  • 12 Oncology, Asan Medical Center, Seoul/KR
  • 13 Medical Oncology, BC Cancer Agency, Vancouver General Hospital University of British Columbia, Vancouver/CA
  • 14 Department Of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si/KR
  • 15 Medical Oncology, The Ottawa Hospital Regional Cancer Centre, Ottawa/CA
  • 16 Pulmonary Diseases, Karolinska University Hospital-Solna, Stockholm/SE
  • 17 Senior Clinical Program Leader, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield/US
  • 18 Bds, Boehringer Ingelheim Ltd UK, Bracknell/GB
  • 19 Ta Oncology, Boehringer Ingelheim GmbH, Ingelheim/DE
  • 20 Division Of Hematology/oncology, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul/KR
More

Resources

Reserved to ESMO members
View the presentation

Background

The irreversible ErbB family blocker, A, and the reversible EGFR TKI, G, are approved for 1st-line treatment (tx) of advanced EGFRm+ NSCLC. In LL7, A (40 mg/d) significantly improved PFS (HR 0.73 [95% CI 0.57–0.95], p = 0.017), ORR (70 vs 56%, p = 0.008) and time to tx failure (TTF; HR 0.73 [0.58–0.92], p = 0.007) vs G (250 mg/d) in this setting. Here, we present primary analysis of mature OS data.

Methods

LL7 assessed A vs G in tx-naïve pts with stage IIIb/IV NSCLC and a Del19/L858R EGFR mutation. Co-primary endpoints were PFS, TTF and OS. Other endpoints included ORR and AEs. Primary OS analysis was planned after ∼213 OS events and follow-up of ≥32 mos.

Results

Events for OS analysis were met at the data cut-off of 8 Apr 2016. Median follow-up for OS: 42.6 mos. Median tx duration: 13.7 (A) vs 11.5 (G) mos. 73/77% (A/G) of pts had ≥1 subsequent systemic anti-cancer treatment after discontinuation of A/G. 46/56% (A/G) received a subsequent EGFR TKI; 20 (14%)/23 (15%) pts (A/G) received a 3rd-gen EGFR TKI. There was a trend towards improved OS with A vs G (median 27.9 vs 24.5 mos; HR 0.86 [0.66–1.12], p = 0.258). Landmark 24-mo and 30-mo OS rates were 61 vs 51% (A vs G) and 48 vs 40% (A vs G); these survival rates with A were similar to the LL3 trial (60 and 50% in pts with common EGFR mutations). Prespecified subgroup analyses showed similar OS trends with A vs G in pts with Del19 (30.7 vs 26.4 mos; HR 0.83 [0.58–1.17]) and L858R (25.0 vs 21.2 mos; HR 0.92 [0.62–1.36]) mutations. There was a trend towards improved OS with A vs G in pts who received a 3rd-gen EGFR TKI (NE vs 46.0 mos; HR 0.51 [0.17–1.52]). In pts treated with A, consistent OS outcomes were observed across age groups (median, mos: 27.9 [≥60 yrs]; 26.7 [≥65 yrs]; 25.1 [≥70 yrs]; 27.9 [≥75 yrs]). Updated PFS, TTF and ORR data were similar to the primary analyses; all were significantly improved with A vs G. The AE profile of A and G was virtually unchanged since the primary analysis.

Conclusions

In LL7, there was no significant difference in OS with A vs G. A trend favouring afatinib, generally consistent across subgroups, was observed. Updated analyses of PFS (independent), TTF and ORR all significantly favoured A over G.

Clinical trial identification

Clinical trial registration: NCT01466660

Legal entity responsible for the study

Boehringer Ingelheim

Funding

Boehringer Ingelheim

Disclosure

L. Zhang: Membership on advisory board/board of directors (AstraZeneca, Lilly). V. Hirsh: Membership on advisory board and honoraria (Boehringer Ingelheim). K. O'Byrne: Honoraria (Pfizer, Roche, AZD, Boehringer Ingelheim, BMS, MSD, Lilly, Novartis); advisory role (Pfizer, Roche, AZD, Boehringer Ingelheim, BMS, MSD, Lilly, Novartis); speaker's bureau (Pfizer, Roche, AZD, Boehringer Ingelheim, MSD, Lilly); travel/accommodation expenses (Roche, AZD, Boehringer Ingelheim, MSD); stock (CARP Pharmaceuticals, Bluesky Biosciences); Patents (TCD Ref LO02-310-01, Australian Provisional Patent 2015905380). M. Boyer: Membership on advisory board or board or directors (AstraZeneca); corporate-sponsored research (AstraZeneca, Boehringer Ingelheim, Clovis, Roche). J.C-H. Yang: Membership on advisory board or board of directors (Boehringer Ingelheim, Eli Lilly, Bayer, Roche/Genentech/Chugai, AstraZeneca, Astellas, MSD, Merck Serono, Pfizer, Novartis, Clovis Oncology, Celgene, innopharma, Merrimack). T.S.K. Mok: Stock (Sanomics Ltd); advisory board (AZ, Roche/Genentech, Pfizer, Eli Lilly, BI, Merck Serono, MSD, Janssen, Clovis Oncology, BioMarin, GSK, Novartis, SFJ Pharmaceutical, ACEA Biosciences, Inc., Vertex Pharmaceuticals, Aveo & Biodesix, BMS, geneDecode Co., Ltd, OncoGenex Technologies Inc.); board of directors (IASLC, Chinese Lung Cancer Research Foundation Ltd, CSCO, HKCTS); corporate-sponsored research (AZ, BI, Pfizer, Novartis, SFJ, Roche, MSD, Clovis Oncology, BMS). J. Fan, A. Märten: Employment (Boehringer Ingelheim). K. Park: Membership on advisory board (Boehringer Ingelheim); corporate-sponsored research (AstraZeneca). All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings